This archive is for reference only. It may not be reflective of the current situation. If you have any queries please use the contact us link.
27/4/2000
Boehringer Ingelheim makes worldwide contribution to the environment
Boehringer Ingelheim today announced the results of its worldwide environmental protection, safety and health policy for 2000. Results show a reduction in emissions, more efficient use of resources, increased recycling and a decline in the number of work-related accidents.
The report, Our planet – our responsibility, gives an account of the operating units’ activities worldwide with illustrations of particular initiatives that have been undertaken at local level.
Dr Hans-Jurgen Leuchs, Managing Director Operations at Boehringer Ingelheim said:
‘Boehringer Ingelheim’s mission is to discover, develop, produce and market medicines which benefit mankind, and in doing so the company assigns high priority to minimising the impact of its activities on the environment in every part of the world where it operates. We consider environmental protection, safety and health as a part of our drive for operational excellence.’
Examples of initiatives that have been undertaken across the world include environmental improvements in Colombia where Boehringer Ingelheim was awarded first prize in a competition for the reduction of emissions supported by the United Nations Environment Programmes. In Japan a number of initiatives proved highly effective in saving energy and reducing waste resulting in a 77 per cent reduction in packaging waste volumes and 16 per cent increase in overall recycling rates.
Our planet - our responsibility can be found on our website at www.boehringer-ingelheim.com.
For further information please contact:
Boehringer Ingelheim
The Boehringer Ingelheim group of companies, with headquarters in Ingelheim, Germany, is one of the 20 leading pharmaceutical corporations in the world. In 2000, it posted revenues of more than EUR 6 billion.
Boehringer Ingelheim, which has some 140 affiliated companies worldwide, focuses on human pharmaceuticals and animal health. The human pharmaceuticals business, which accounts for 95% of sales, comprises of prescription medicines, consumer health care products and chemicals and biopharmaceuticals for industrial customers. Research and development, production, and distribution facilities are located around the globe. In 2000, Boehringer Ingelheim spent almost EUR 1.0 billion on R&D, equivalent to 16% of net sales.
For more information on Boehringer Ingelheim, please see the international Internet website www.boehringer-ingelheim.com
This news story was brought to you by Boehringer Ingelheim - the largest family-owned pharmaceutical company in the world.
What do you want to do now?
